In contrast to these earlier results, we found that the group I PAK inhibitor G-5555 [23] partially suppressed the BRAFi-resistant phenotype of Rac1-driven drug-resistant melanoma cells in the presence of BRAFi treatment (vemurafenib; VEM) (Fig. 2A, B), but did not reduce cell survival in the absence of BRAFi treatment (Supplementary Fig. S1). The gene discussed is RAC1; the disease is melanoma.